Blog
GLP-1 News & Updates
FDA updates, drug pricing news, insurance coverage changes, and the latest clinical trial results for GLP-1 weight loss medications.
First Generic GLP-1 Hits Market as Liraglutide Shortage Continues
Generic liraglutide becomes first GLP-1 with generic availability, offering hope for lower costs while brand shortage persists.
The DoseLilly's Retatrutide Delivers Record 28.7% Weight Loss in First Phase 3 Trial
Eli Lilly's triple-agonist retatrutide achieved 28.7% average weight loss (71.2 pounds) in its first successful Phase 3 trial, setting a new efficacy record for obesity medications.
The DoseFDA Approves Foundayo: Eli Lilly's GLP-1 Pill with No Food Restrictions
Eli Lilly's Foundayo becomes the second GLP-1 pill approved for weight loss, offering unique flexibility with no food or water restrictions and $149 starting price.
The DoseFDA Delays Orforglipron Decision to April Amid Priority Voucher Program Setbacks
The FDA pushed back Eli Lilly's highly anticipated oral GLP-1 pill decision by two weeks to April 10, marking the first major delays in the new priority review program.
The DoseFDA Approves Wegovy HD: First High-Dose GLP-1 Delivers Record 20.7% Weight Loss
FDA fast-tracked approval of Wegovy HD (7.2 mg semaglutide) under new priority program, achieving highest weight loss on record for any GLP-1 injection.
The DoseEli Lilly's Triple Agonist Retatrutide Achieves 2% A1C Drop in Phase 3
Lilly's experimental retatrutide delivered up to 2% A1C reduction and 16.8% weight loss in its first Phase 3 diabetes trial, positioning it as a potential challenger to current GLP-1 therapies.
The DoseFDA Issues 30 Warning Letters in Major GLP-1 Compounding Crackdown
The FDA sent warning letters to 30 telehealth companies on March 3, marking the largest enforcement action against compounded GLP-1 marketing in the agency's history.
The DoseNew Protein Research Redefines Muscle Preservation on GLP-1 Medications
Major studies reveal people on GLP-1s need 1.5-2.3g protein per kg of lean body mass daily to prevent muscle loss, with new 'protein pacing' strategies emerging as game-changers.
The DoseFour States Drop GLP-1 Obesity Coverage as Federal Expansion Model Launches
California, Pennsylvania, New Hampshire, and South Carolina eliminated Medicaid GLP-1 obesity coverage in January 2026, reducing state coverage from 16 to 13 states despite new federal BALANCE model.
The DoseWalgreens Disrupts GLP-1 Market with Subscription-Free Weight Management
Major retail pharmacy launches $49 pay-per-visit GLP-1 program in 28 states, challenging telehealth subscription model with no monthly fees required.
The DoseMajor Medical Groups Release First Joint Nutrition Guidelines for GLP-1s
Four leading medical organizations publish comprehensive nutritional guidelines for GLP-1 therapy, emphasizing the importance of personalized nutrition and lifestyle support.
The DoseCMS Launches BALANCE Model to Expand GLP-1 Access in Medicare and Medicaid
The Trump administration's new BALANCE model aims to expand access to GLP-1 medications for weight management in Medicare and Medicaid through negotiated pricing, launching May 2026.